Complexity of β-lactamases among clinical Aeromonas isolates and its clinical implications

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

Aeromonas species, aquatic Gram-negative bacilli, distributed globally and ubiquitously in the natural environment, may be implicated in a variety of human diseases. They can produce various β-lactamases which confer resistance to a broad spectrum of β-lactams, and therefore in vitro susceptibility testing must be used to guide antimicrobial therapy. However, conventional in vitro susceptibility tests may sometimes fail to detect these β-lactamases, and hence raise a therapeutic challenge. In this review article, two chromosomally mediated β-lactamases (i.e., AmpC β-lactamases and metallo-β-lactamases) and acquired extended-spectrum β-lactamases in aeromonads are reviewed, and the clinical implications of the complexity of β-lactamases are discussed.

Original languageEnglish
Pages (from-to)398-403
Number of pages6
JournalJournal of Microbiology, Immunology and Infection
Volume45
Issue number6
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Aeromonas
Lactams
Bacillus
Therapeutics
In Vitro Techniques

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology and Microbiology(all)
  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{27d00c8d8b784dfe8046e93de81b6710,
title = "Complexity of β-lactamases among clinical Aeromonas isolates and its clinical implications",
abstract = "Aeromonas species, aquatic Gram-negative bacilli, distributed globally and ubiquitously in the natural environment, may be implicated in a variety of human diseases. They can produce various β-lactamases which confer resistance to a broad spectrum of β-lactams, and therefore in vitro susceptibility testing must be used to guide antimicrobial therapy. However, conventional in vitro susceptibility tests may sometimes fail to detect these β-lactamases, and hence raise a therapeutic challenge. In this review article, two chromosomally mediated β-lactamases (i.e., AmpC β-lactamases and metallo-β-lactamases) and acquired extended-spectrum β-lactamases in aeromonads are reviewed, and the clinical implications of the complexity of β-lactamases are discussed.",
author = "Po-Lin Chen and Wen-Chien Ko and Wu, {Chi Jung}",
year = "2012",
month = "12",
day = "1",
doi = "10.1016/j.jmii.2012.08.008",
language = "English",
volume = "45",
pages = "398--403",
journal = "Journal of Microbiology, Immunology and Infection",
issn = "1684-1182",
publisher = "Elsevier Taiwan LLC",
number = "6",

}

Complexity of β-lactamases among clinical Aeromonas isolates and its clinical implications. / Chen, Po-Lin; Ko, Wen-Chien; Wu, Chi Jung.

In: Journal of Microbiology, Immunology and Infection, Vol. 45, No. 6, 01.12.2012, p. 398-403.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Complexity of β-lactamases among clinical Aeromonas isolates and its clinical implications

AU - Chen, Po-Lin

AU - Ko, Wen-Chien

AU - Wu, Chi Jung

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Aeromonas species, aquatic Gram-negative bacilli, distributed globally and ubiquitously in the natural environment, may be implicated in a variety of human diseases. They can produce various β-lactamases which confer resistance to a broad spectrum of β-lactams, and therefore in vitro susceptibility testing must be used to guide antimicrobial therapy. However, conventional in vitro susceptibility tests may sometimes fail to detect these β-lactamases, and hence raise a therapeutic challenge. In this review article, two chromosomally mediated β-lactamases (i.e., AmpC β-lactamases and metallo-β-lactamases) and acquired extended-spectrum β-lactamases in aeromonads are reviewed, and the clinical implications of the complexity of β-lactamases are discussed.

AB - Aeromonas species, aquatic Gram-negative bacilli, distributed globally and ubiquitously in the natural environment, may be implicated in a variety of human diseases. They can produce various β-lactamases which confer resistance to a broad spectrum of β-lactams, and therefore in vitro susceptibility testing must be used to guide antimicrobial therapy. However, conventional in vitro susceptibility tests may sometimes fail to detect these β-lactamases, and hence raise a therapeutic challenge. In this review article, two chromosomally mediated β-lactamases (i.e., AmpC β-lactamases and metallo-β-lactamases) and acquired extended-spectrum β-lactamases in aeromonads are reviewed, and the clinical implications of the complexity of β-lactamases are discussed.

UR - http://www.scopus.com/inward/record.url?scp=84870291269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870291269&partnerID=8YFLogxK

U2 - 10.1016/j.jmii.2012.08.008

DO - 10.1016/j.jmii.2012.08.008

M3 - Review article

C2 - 23031536

AN - SCOPUS:84870291269

VL - 45

SP - 398

EP - 403

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

SN - 1684-1182

IS - 6

ER -